Early efficacy data with a newer generation of LTD4 antagonists in antiasthma trials: early promise for a single mediator antagonist.
Cheng
J B
JB
Department of Immunology and Infectious Diseases, Pfizer Inc., Groton, Connecticut 06340.
D000098:Acetophenones / Q000627:therapeutic use; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000209:etiology; D001993:Bronchodilator Agents / Q000627:therapeutic use; D006801:Humans; D007211:Indoles; D048448:Phenylcarbamates; D011422:Propionates / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D013189:SRS-A / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013449:Sulfonamides; D013777:Tetrazoles / Q000627:therapeutic use; D014105:Tosyl Compounds / Q000627:therapeutic use
D000098:Acetophenones; D001993:Bronchodilator Agents; D007211:Indoles; D048448:Phenylcarbamates; D011422:Propionates; D011804:Quinolines; D013189:SRS-A; D013449:Sulfonamides; D013777:Tetrazoles; D014105:Tosyl Compounds; C059141:verlukast; C044660:LY 171883; C062735:zafirlukast